Month: March 2023

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 30, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2022. Vivos believes that its 2022 and early 2023 accomplishments, including the completion of a capital raise for net proceeds...

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– Full enrollment of the LUNA trial anticipated in the second half of 2023 – – LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 – – LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023 – – Cash runway into 2025 – REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular...

Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

– FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate – – Completed dosing in ongoing Phase 1 study of IVX-A12; topline interim results expected in 2Q 2023 – – Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 – – Cash and cash equivalents, restricted cash, and short-term investments of $219.4M at end 4Q 2022 – SEATTLE, March 30, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial...

HeartCore Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK and TOKYO, March 30, 2023 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (“HeartCore” or “the Company”), a leading software development company offering Customer Experience Management Platform (“CXM Platform”) and Digital Transformation (“DX”), reported financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Operational HighlightsGrew total number of global enterprise customers to 903 as of December 31, 2022. Established HeartCore Capital Advisors, Inc., a subsidiary that will execute Go IPO and provide professional consulting services to Japanese companies seeking to list on a major U.S. exchange. Partnered with Works Applications and AIM Consulting to improve their respective digital auditing solutions through its DX suite of offerings. Signed eighth and ninth...

BW Energy: Notification of trade

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Notification of trade With reference to BW Offshore’s stock exchange release dated 30 March 2023, please observe the following. BW Offshore has entered into a Total Return Swap (“TRS”) agreement with financial exposure to 353 425 shares in BW Energy Limited (“BWE”). The TRS agreement relates to BW Offshore’s Long-Term Incentive Programme (LTIP) adopted in 2019. Expiry date for the TRS agreement is 5 April 2024, and the TRS price is NOK 27.92 per share. Please see BW Offshore’s stock exchange release for more information. For further information, please contact: Knut R. Sæthre, CFO BW Energy, +47 91 11 78 76 ir@bwenergy.no BW Energy is a growth E&P company with a differentiated strategy targeting proven offshore oil and gas reservoirs through low risk phased developments. The Company...

Fitch upgrades JDE Peet’s to BBB; Outlook Stable

Written by Customer Service on March 30, 2023. Posted in Public Companies.

PRESS RELEASE Amsterdam, 30 March 2023 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company by revenue, today announced that Fitch Ratings has upgraded the company’s credit rating from ‘BBB-‘ to ‘BBB’ with a stable outlook. This upgrade underscores the company’s operating strength, strong financial structure and financial discipline. In its release, Fitch noted: “The upgrade reflects the company’s recent de-leveraging and Fitch’s confidence that management will continue to meet its conservative net debt/EBITDA target of about 2.5x. The rating reflects JDEP’s strong market position in the global coffee industry with strong and broadly stable profitability, supported by the sector’s low price elasticity and the potential for further premiumisation of the company’s products. This combines with low capex requirements...

Amerant Investments Appoints Baylor Lancaster-Samuel as Chief Investment Officer

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Finance veteran to enhance Amerant Bank’s investment research effortsBaylor Lancaster-Samuel Amerant Investments, Inc., a subsidiary of Amerant Bank, today announced Baylor Lancaster-Samuel has been appointed to Chief Investment Officer.MIAMI, March 30, 2023 (GLOBE NEWSWIRE) — Amerant Investments, Inc., a subsidiary of Amerant Bank, today announced Baylor Lancaster-Samuel, an investment professional with over 20 years of experience, has been appointed to Chief Investment Officer. Lancaster-Samuel will manage the Amerant Investments research team and help craft and deliver investment research views to internal colleagues and clients. Lancaster-Samuel joined Amerant in 2021 as a Fixed Income Portfolio Manager and was later promoted to Senior Fixed Income Strategist. Prior to joining Amerant, she worked in credit research...

FOMO WORLDWIDE REPORTS 137% PRO FORMA REVENUE GROWTH TO $8.8 MILLION IN 2022; UPDATES INVESTORS ON STRATEGY AND PLANNED ACQUISITIONS

Written by Customer Service on March 30, 2023. Posted in Public Companies.

Pittsburgh, PA, March 30, 2023 (GLOBE NEWSWIRE) — FOMO WORLDWIDE, INC. (US OTC: FOMC) today announces that the Company generated roughly $8.8 million pro forma revenues in 2022 (consolidated and unaudited), up from $4.3 million in 2021 and $3.2 million in 2020, representing annual pro forma growth of 137% and a high double digit % compound annual growth rate (CAGR). On a reported basis, 2022 revenues grew over 1,000% from the prior year. Gains were primarily driven by strong K12 demand. Orders that had been largely unfulfilled due to pandemic closures and supply chain constraints led to record backlog at FOMO’s primary subsidiary SMARTSolution Technologies L.P. (“SST”) acquired in 2022. In the period, SST’s equipment sales were roughly $8.3 million (93%), service and installation revenues were roughly $529,000 (6.9%), and shipping...

CNL Strategic Capital Announces Year-End Operating Results for 2022

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

Orlando, Fla., March 30, 2023 (GLOBE NEWSWIRE) — CNL Strategic Capital, LLC (“CNL Strategic Capital,” the “Company” or “we”) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses. The Company announced its operating results for the year ended Dec. 31, 2022. Highlights:As of Dec. 31, 2022, CNL Strategic Capital’s portfolio consisted of equity and debt investments in 11 portfolio companies and had approximately $732.5 million in total assets, compared with approximately $514.8 million as of Dec. 31, 2021. For the year ended Dec. 31, 2022, the Company recognized a net change in unrealized appreciation on investments of approximately $41.3 million and had total investment income of approximately...

CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 30, 2023. Posted in Earnings Releases And Operating Results.

ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) — In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected release follows:Total revenue for 2022 was approximately $2.6 million Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million Conference call to be held March 29, 2023 at 4:30 p.m. ETOpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2022 and full-year 2022 financial and operating results and provided a business update. OpGen’s revenue for the fourth quarter of 2022 was approximately $722 thousand. Its total revenue for 2022 was...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals